OPKO Health, Inc. Market Research Report
Company Overview
- Name: OPKO Health, Inc.
- Mission: Focused on improving patients' lives by delivering next-generation solutions for serious diseases across established global markets.
- Founded: No information is available.
- Founders: No information is available.
- Key People:
- Phil Frost: CEO and Chairman
- Jane Hsiao: CTO and Vice Chairman
- Dr. Giovanni Abbadessa, M.D., Ph.D.: Chief Medical Officer
- Elias A. Zerhouni M.D.: President of OPKO Health and Vice Chairman
- Gary J. Nabel: Chief Innovation Officer and Director
- John Mascola: CSO of ModeX Therapeutics
- Steve Rubin: Executive Vice President, Administration
- Adam Logal: Senior Vice President and CFO
- Charles Bishop: CEO of OPKO Renal
- Tony Cruz: President of Transition Therapeutics
- Hans Berner: President, OPKO Health Iberoamerica
- Damien Burke: CEO, Eirgen Pharma
- Arie Gutman: President of API
- Headquarters: 4400 Biscayne Boulevard, Miami, FL 33137
- Number of Employees: No information is available.
- Revenue: Consolidated total revenues for third quarter 2024 were $173.6 million.
- Known For: Multispecialty healthcare company involved in biopharmaceuticals, diagnostics, and developing therapies for serious diseases.
Products
NGENLA™
- Description: A next-generation human growth hormone therapy for pediatric patients with growth hormone deficiency.
- Key Features:
- FDA-approved once-weekly human growth hormone analog.
- Approved in over 40 markets worldwide.
- Developed in partnership with Pfizer.
RAYALDEE®
- Description: An extended-release oral formulation of calcifediol indicated for patients with secondary hyperparathyroidism and vitamin D insufficiency.
- Key Features:
- Approved by the FDA to raise serum total 25D and lower iPTH levels.
- Treats SHPT in adults with stage 3 or 4 CKD.
Recent Developments
- New Products/Developments:
- Extended-Release Calcifediol: Highlighted data from Phase 3 studies to real-world evidence to enhance early treatment of secondary hyperparathyroidism.
- Partnerships:
- Entered a $250 million note purchase agreement with HealthCare Royalty related to profit share payments of NGENLA™.
- Sale of select BioReference Health assets to Labcorp for $237.5 million, focusing on oncology and urology diagnostics.
- Financial Results:
- Achieved operating income of $14.2 million for the third quarter of 2024, reversing a prior year’s quarter operating loss.
- Announced a $100 million share repurchase program.
- R&D Initiatives:
- Enrollment in MDX2001 Phase 1 trial to treat solid tumor cancers.
- Received $51 million additional funding under a BARDA contract for COVID multispecific antibodies and influenza program development.
- Corporate Actions:
- Board of Directors authorized share repurchase and retired significant shares.
Locations
- North America:
- OPKO Health
- OPKO Renal
- BioReference Laboratories
- GenPath Oncology
- GenPath Women’s Health
- ModeX Therapeutics
- Middle East:
- OPKO Biologics
- Finetech
- Europe:
- Eirgen Pharma
- OPKO EU
- Latin America:
- OPKO Chile
Additional Information
- OPKO Health continues to leverage its research into multispecific therapies, advancing treatments for cancers and infectious diseases, in collaboration with partners such as Merck and NIH.
- Revenue analyses show strong royalty payments particularly from the collaborative ventures involving Pfizer’s Genotropin and NGENLA in pediatric and other indications.
Contact Information
- Address: 4400 Biscayne Boulevard, Miami, FL 33137
- Phone: 305-575-4100
- Email: contact@opko.com
---
This comprehensive report encapsulates crucial data points on OPKO Health, Inc.'s operations, strategic initiatives, and market activities as of the latest financial and corporate updates available as of November 2024.
